More adults with social disadvantage receiving 8-week vaporized nicotine products vs. nicotine replacement therapy achieved 6 ...

In this video, Ashkan M. Abbey, MD, FASRS, FAAO, of Texas Retina Associates, discusses his presentation at Clinical Trials at the Summit on the use of EyePoint’s Duravyu in neovascular age-related ...